Infermedica Medical Guidance Platform (triage, intake, follow-up) incl. Conversational Triage
Infermedica · Triage call centers, telehealth, digital front door, virtual care, emergency triage · API-first SaaS, white-label (voice or screen)
Clinical Evidence & Decision Support
Infermedica's Medical Guidance Platform provides AI-driven triage, intake, and follow-up decision support that routes patients to the right level of care with transparent, explainable logic. Its neurosymbolic engine combines LLMs with a clinician-curated medical knowledge base, and the platform is certified as a Class IIb medical device under the EU MDR.
Evidence at a glance
Freshness, source-checked counts, confidence and gate results below reflect the frozen evidence snapshot through . A later editorial review does not update these results.
- Stated intended users
- Health systems, telehealth and telemedicine providers, insurers/payers, governments (national digital front doors), pharmacies
- Documentary gate at snapshot
- Failed
- Scenario match
- No evaluated buying scenario currently covers this product
- Comparability
- Not yet comparable in this scenario
- Decision readiness at snapshot
- HISTORICAL — Research only
- Documented evidence at snapshot
- 1 of 4 evidence claims source-checked · confidence Unknown
- Critical unknowns
- scaled production deployment · verified interoperability evidence · security and governance evidence · documented economic outcomes
- Latest checked-source retrieval in snapshot
- 2026-08-27
Expand each claim to inspect its source, dates and recorded verification status.
vendor pageInfermedica's Medical Guidance Platform (Triage, Intake, Follow-up modules) achieved EU MDR Class IIb certification, one of the highest comp…2026-01-07
Exact claim. Infermedica's Medical Guidance Platform (Triage, Intake, Follow-up modules) achieved EU MDR Class IIb certification, one of the highest compliance levels for Software as a Medical Device in Europe; Conversational Triage, its agentic neurosymbolic AI product launched April 2025, is in the process of MDR certification expected 2026
- Source
- infermedica.com
- Type
- vendor page
- Published
- 2026-01-07
- Retrieved
- 2026-08-27
- Verification
- unverified
- Confidence
- not stated
- Reviewer
- healthit-gate-v1
- Claim version
- v1
- Supports
- trust_governance
Self-reported by the vendor. Independent verification is pending unless marked otherwise.
Open infermedica.comvendor pageInfermedica's solutions crossed 25 million completed health checkups and, with Healthdirect Australia, generated a 71% increase in self-asse…2026-01-07
Exact claim. Infermedica's solutions crossed 25 million completed health checkups and, with Healthdirect Australia, generated a 71% increase in self-assessment completion rates, a 9% improvement in triage accuracy, and a 46% reduction in overtriage versus the legacy system, serving 26 million Australians
- Source
- infermedica.com
- Type
- vendor page
- Published
- 2026-01-07
- Retrieved
- 2026-08-27
- Verification
- unverified
- Confidence
- not stated
- Reviewer
- healthit-gate-v1
- Claim version
- v1
- Supports
- deployment_traction
Self-reported by the vendor. Independent verification is pending unless marked otherwise.
Open infermedica.compress releaseInfermedica was named to AVIA Marketplace's 2024 Top Clinical Decision Support Companies list2024-06-15
Exact claim. Infermedica was named to AVIA Marketplace's 2024 Top Clinical Decision Support Companies list
- Source
- prnewswire.com
- Type
- press release
- Published
- 2024-06-15
- Retrieved
- 2026-08-27
- Verification
- excerpt_matched
- Confidence
- not stated
- Reviewer
- healthit-gate-v1
- Claim version
- v1
- Supports
- market_durability
- Score contribution
- Feeds market durability
Vendor or press announcement. Verify material claims against primary filings or contracts.
Open prnewswire.comindependent reportInfermedica raised a $30M Series B led by One Peak (January 2022), bringing total funding to roughly $44M, to expand its AI-based medical gu…2022-01-25
Exact claim. Infermedica raised a $30M Series B led by One Peak (January 2022), bringing total funding to roughly $44M, to expand its AI-based medical guidance platform
- Source
- techcrunch.com
- Type
- independent report
- Published
- 2022-01-25
- Retrieved
- 2026-08-27
- Verification
- unverified
- Confidence
- not stated
- Reviewer
- healthit-gate-v1
- Claim version
- v1
- Supports
- market_durability
- Score contribution
- Feeds market durability
Independent source. Methodology and sample vary by report; read the underlying method.
Open techcrunch.comVerified provider experience is not yet publishable. Fewer than five independent provider organizations have contributed eligible reviews. Reviewer mode is off. Experience never changes documentary scoring, freshness, or rank.
Buyer lenses — evidence-backed bands at snapshot (not a 0–100 rank)
Deployment, integration, data handling at snapshot
- Integration maturity
- live — Listed on an EHR marketplace/partner program — live distribution.
- EHR path
- UNKNOWN
Why unknown
Why. No reliable source on file. The platform does not infer values from weak sources.
What would close it. A primary source or independent verification.
- FHIR / API
- UNKNOWN
Why unknown
Why. No reliable source on file. The platform does not infer values from weak sources.
What would close it. A primary source or independent verification.
- SSO
- UNKNOWN
Why unknown
Why. Single-sign-on support is not documented in vendor or marketplace materials on file.
What would close it. Vendor security documentation or marketplace listing mentioning SSO/SAML/OIDC.
- PHI / BAA
- EU-headquartered GDPR-aligned company; clinical guidance outputs governed by MDR Class IIb SaMD certification; multi-agent/EHR integration in roadmap for 2026
- Security attestations
- UNKNOWN
- FDA status
- UNKNOWN
Why unknown
Why. No FDA listing found for this product's functions in the tracked category.
What would close it. An FDA 510(k)/De Novo listing, or a clear statement that no regulated function is claimed.
- Pricing
- Not publicly listed
Technical provenance
snap_36bba25c577cbb44 · Evidence cutoff: 2026-08-27T04:05Z · Snapshot generated: 2026-10-21T19:39Z · build ffbf5c3
Forecast calibration is not in the public snapshot — shown as UNKNOWN rather than read from SQLite.
Known limitations
- Deployment traction is UNKNOWN.
Why unknown
Why. No reliable source on file. The platform does not infer values from weak sources.
What would close it. A primary source or independent verification.
- Interoperability is UNKNOWN.
Why unknown
Why. No reliable source on file. The platform does not infer values from weak sources.
What would close it. A primary source or independent verification.
- Trust & governance is UNKNOWN.
Why unknown
Why. No reliable source on file. The platform does not infer values from weak sources.
What would close it. A primary source or independent verification.
- Economic value evidence is UNKNOWN.
Why unknown
Why. No independently verifiable ROI claim (peer-reviewed, audited case, or independent benchmark) is on file.
What would close it. An audited implementation report or peer-reviewed study with payback/throughput numbers.